In a country noted for its efficiency and process-driven approach, Japan’s pharmaceutical industry and its bureaucratic, bloated drug approval process, remained a tarnish on its reputation on the worldwide stage.

But the industry has undergone something of a renaissance in recent years, driven by  breakthroughs in technology, regulatory reforms, and a focus on global collaboration that is better equipping the sector for future success.

As Japan takes these lessons from the past and embraces a future of agility and innovation, the country is fast becoming a magnet for global suppliers and a haven for pharmaceutical progress.

All this culminates with CPHI Japan 2025, an industry mainstay that is set to welcome over 20,000 professionals and 680 exhibitors from 50 nations in Tokyo between 9-11 April.

Regulatory Reform and Revision

The industry’s evolution has been made against a regulatory backdrop in which new therapies, routinely available in the West, were either delayed or never approved for Japanese patients – an observation commentators termed as Japan’s ‘drug loss.’ The country’s ageing population and spiralling healthcare costs also laid bare the urgency for change.

In response, the Japan’s Ministry of Health, Labour and Welfare (MHLW) began the reforms needed to speed up approvals and simplify the process of carrying out local clinical trials – actions that represented an opportunity, according to private equity firm Bain.

Commenting on last month’s $3.3bn (€3.05bn) acquisition of drug firm Tanabe, David Gross, co-managing partner of Bain Capital and its lead in Asia, told the Financial Times, “This kind of carve-out partnership, which couples knowledge and experience of Japan with really deep scientific expertise . . . is one of the most effective solutions to solving the drug loss problem in Japan and turning around the growth of major pharmaceutical companies.”

The eagerness to acquire these ‘drug loss’ assets’ meant not only pharmaceutical firms were interested but also trading companies, contract research organisations (CROs), and wholesalers, all anticipating the dismantling of the obstacles deterring foreign firms.

Indeed, EPS Holdings, Suzuken Group, and Bushu Pharmaceuticals have collaborated to support the introduction of unapproved drugs into the Japanese market recognizing that around 70% of new drugs approved in Europe and the U.S. over the past five years remain unapproved in Japan.

Additionally, the Japan arm of Recordati Rare Diseases are currently in licensing negotiations with overseas biotech firms to acquire drug candidates that might end up not reaching the Japanese market.

Innovation at its Core

The thawing of this regulatory rigour is matched by a technological surge that is redefining drug development not only in Japan but in global markets.

With the advent of Artificial intelligence (AI), data analytics, and advanced biotechnologies, the drug development process has been radically streamlined both in terms of timelines and costs.

This is especially evident in peptide and oligonucleotide chemistry – areas in which Japan have traditionally excelled and led the way.

“We’re collaborating with Tides to introduce a free conference in response to the growing interest in oligos and peptides manufacturing in Japan,” said Jenny Leung, Brand Manager at CPHI Japan in 2024. “The increased interest is attributed to a proactive regulatory framework and the country’s strong base of peptide and oligonucleotide chemistry and synthesis.”

Arguably more headline-worthy, AI-driven drug discovery and digital health initiatives are also accelerating progress, driven by collaborative efforts like the Global Health Innovative Technology (GHIT) Fund—linking government, academia, and industry— to address rare diseases and oncology.

In 2023, GHIT gave their backing to a global partnership with the University of Tokyo, University of Oxford, University of Dundee, and Medicines for Malaria Venture (MMV) to use fragment-based screening methods ion developing drug treatments for malaria.

The initiative objectives involved generating high-quality hit compounds against two validated malaria targets, ‘Pf DPCK’ and ‘Pf KRS.’

The researchers harnessed AI-driven optimization methods to design and synthesize compounds with a stronger binding affinity to these targets, providing potentially new starting points for antimalarial drug therapies. ​

A Gateway to Opportunity

According to Frost and Sullivan, Japan’s pharmaceutical sector stands out in market size as the world’s third-largest market, valued at $82.67bn (€75.75bn).

Along with regulatory reforms and a boom in research and development, the prospect of near-simultaneous drug launches with Western markets is a game-changer, particularly for firms in biologics and high-value therapies.

Yet, success demands finesse. By applying a laser-like focus and a due diligence on specific areas, substantial opportunities present themselves both for global suppliers and investors.

These high value therapies extend towards advancements in regenerative medicine, where Japan has carved out a leading role, driven by supportive regulatory frameworks and substantial market growth.

The enactment of the 2014 Pharmaceuticals and Medical Devices (PMD) Act established an expedited approval pathway for regenerative therapies, allowing conditional approval after early-phase trials. This regulatory environment has catalysed rapid advancements in the sector.

As of March 2023, 19 such therapies have received approval, addressing conditions ranging from certain cancers to spinal muscular dystrophy and heart failure.

The first of these was JACE, an autologous cultured epidermis product developed by Japan Tissue Engineering Co., Ltd. (J-TEC) and approved in 2007 for treating severe burns and other skin conditions.

Fast forward to June 2025, where Osaka City is set to inaugurate Nakanoshima Qross, an international hub designed to accelerate the industrialization of regenerative medicine.

This facility is equipped to work on innovations such as the development of  cardiac muscle sheets made from cardiomyocytes derived from induced pluripotent stem cells (iPS cells).

Recent policy has also been directed towards reducing healthcare expenditures by encouraging the use of generic drugs. The government’s “Roadmap to Further Promote the Use of Generic Medicines” outlined a bold target to boost the volume share of generics to over 80% by 2020 – an objective that was achieved.

Pharmaceutical firms have moved to strengthen their positions in the generics market. Kirin Holdings acquired supplement maker Fancl in 2024, with the intention of building its healthcare segment through quality products.

CPHI Japan: A Pharma Powerhouse

The future of Japan’s pharmaceutical industry may finally be realised as streamlined drug approvals draw in much needed investment, while digital adoption increases competitiveness.

Global collaborations such as those formed by Bain Capital’s acquisition of Tanabe Pharma coupled with initiatives like the GHIT Fund advance pharmaceutical research, development, and public health initiatives.

As always, CPHI Japan—­­­­­­Asia’s premier pharma gathering—will remain central to this ascent, weaving Japan ever tighter into the global tapestry.

The event has evolved into a linchpin for this revitalised sector. In 2025, the event will be hosted at Tokyo Big Sight (Tokyo International Exhibition Center) inviting attendees to explore contract services, machinery, packaging, and digital innovations.

Seminars on regulatory trends and market forecasts, coupled with business matchmaking services, ensure that CPHI Japan is more than an exhibition—it’s a catalyst for progress.

The combination of reform, technology, and connectivity align to assert Japan as a pharmaceutical titan. For the industry’s players, from Tokyo to London, the opportunity is ripe—and the time to act is now.